Imatinib Krka D.D.

Imatinib, the active ingredient in Imatinib Krka D.D., is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats certain blood cancers and gastrointestinal stromal tumors in adult patients.

GNH USA supplies Imatinib Krka D.D. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Imatinib is a targeted therapy used in hematologic malignancies and selected solid tumours that depend on specific tyrosine‑kinase signalling pathways.

- Chronic myeloid leukemia (CML): achieves disease control by suppressing BCR‑ABL‑driven leukemic cell proliferation. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): helps attain remission through inhibition of the same BCR‑ABL driver. - Gastrointestinal stromal tumor (GIST): reduces tumour growth by blocking c‑KIT and PDGFR signalling.

Imatinib may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Edema (peripheral swelling) - Muscle cramps or pain - Fatigue - Diarrhoea - Rash or skin irritation

Serious or Rare Side Effects: - Hepatotoxicity (elevated liver enzymes, hepatitis) - Severe neutropenia or thrombocytopenia - Cardiac failure or reduced left‑ventricular ejection fraction - Pulmonary arterial hypertension - Severe skin reactions (Stevens‑Johnson syndrome, toxic epidermal necrolysis) - Tumour lysis syndrome

Before initiating therapy, clinicians should assess baseline organ function and monitor patients regularly.

- Blood counts: monitor complete blood count weekly during the first month, then periodically. - Liver function: check hepatic enzymes before treatment and at regular intervals. - Cardiac assessment: evaluate cardiac status in patients with pre‑existing heart disease. - Drug interactions: review concomitant medications that affect CYP3A4 metabolism. - Pregnancy and lactation: avoid use unless the potential benefit justifies the risk; safety data are limited. - Store below 25°C: keep in the original packaging, protect from moisture and direct light.

Imatinib interacts with several medicines that influence its metabolism or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise imatinib plasma levels. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may markedly reduce efficacy. - Antacids containing aluminium or magnesium: can impair absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR. - Diuretics (e.g., furosemide): increased risk of fluid retention and electrolyte imbalance. - QT‑prolonging agents (e.g., sotalol, quinidine): monitor cardiac rhythm for arrhythmias.